<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03927690</url>
  </required_header>
  <id_info>
    <org_study_id>CLKA651X2202</org_study_id>
    <nct_id>NCT03927690</nct_id>
  </id_info>
  <brief_title>Multiple Dose Safety and Efficacy of LKA651 in Patients With Diabetic Macular Edema</brief_title>
  <official_title>A Randomized, Active-controlled, Patient and Investigator-masked, Multiple Dose Proof-of-concept Study of Intravitreal LKA651 in Patients With Diabetic Macular Edema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and efficacy of LKA651 in patients with macular edema from diabetic
      macular edema (DME),
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 23, 2019</start_date>
  <completion_date type="Anticipated">February 9, 2021</completion_date>
  <primary_completion_date type="Anticipated">February 9, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse event profile and safety endpoints of LKA651</measure>
    <time_frame>Day 169</time_frame>
    <description>Incidence of treatment emergent adverse events and study drug related adverse events.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of LKA651 on Best Corrected Visual Acuity (BCVA)</measure>
    <time_frame>Day 85</time_frame>
    <description>To determine Best Corrected Visual Acuity (BCVA) as assessed by ETDRS (Early Treatment Diabetic Retinopathy Study) visual acuity charts</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of LKA651 on Central subfield retinal thickness</measure>
    <time_frame>Day 85</time_frame>
    <description>Change from baseline in Central subfield retinal thickness as measured by SD-OCT</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the time to retreatment with anti-VEGF</measure>
    <time_frame>Day 169</time_frame>
    <description>To determine the time to retreatment with anti-VEGF (as determined by PI) after week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of LKA651 at steady state in patients with diabetic macular edema</measure>
    <time_frame>Day 169</time_frame>
    <description>To assess the Cmax of LKA651 at steady state in patients with diabetic macular edema</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of ranizumab at steady state in patients with diabetic macular edema</measure>
    <time_frame>Day 169</time_frame>
    <description>To assess the Cmax of ranizumab at steady state in patients with diabetic macular edema</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-28 of LKA651 at steady state in patients with diabetic macular edema</measure>
    <time_frame>Day 169</time_frame>
    <description>To assess the AUC0-28 of LKA651 at steady state in patients with diabetic macular edema</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-28 of ranizumab at steady state in patients with diabetic macular edema</measure>
    <time_frame>Day 169</time_frame>
    <description>To assess the AUC0-28 of ranizumab at steady state in patients with diabetic macular edema</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of IVT LKA651 when administered alone or in combination with Lucentis® on DR progression in patients with DME</measure>
    <time_frame>Day 169</time_frame>
    <description>effect of IVT LKA651 when administered alone or in combination with Lucentis® on DR progression in patients with DME by improvement in the diabetic retinopathy severity scale by color fundus photos</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Diabetic Macular Edema</condition>
  <arm_group>
    <arm_group_label>LKA651</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LKA651 IVT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LKA651/Lucentis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LKA651/Lucentis IVT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lucentis</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lucentis IVT</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LKA651</intervention_name>
    <description>LKA651 IVT</description>
    <arm_group_label>LKA651</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LKA651</intervention_name>
    <description>LKA651 IVT</description>
    <arm_group_label>LKA651/Lucentis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lucentis</intervention_name>
    <description>Lucentis IVT</description>
    <arm_group_label>LKA651/Lucentis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lucentis</intervention_name>
    <description>Lucentis IVT</description>
    <arm_group_label>Lucentis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          1. Written informed consent must be obtained before any assessment is performed.

          2. Male and female patients age 18 to 85 years of age inclusive at screening

          3. Presence of type I or type II diabetes mellitus

          4. The ETDRS letter score in the study eye must be between 24 and 70 letters (approximate
             Snellen equivalent of 20/40-20/320). The non-study eye (fellow eye) should be ≥34
             letters or better (approximate Snellen equivalent of 20/200) at screening

          5. Presence of DME in the study eye, with decrease in vision due to foveal thickening of
             central macular thickness ≥ 320 µm in the central subfield, as assessed on SD-OCT and
             confirmed by the central reading center at screening

        Other protocol specified inclusion/exclusion criteria apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
    <email>Novartis.email@novartis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <zip>89502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <zip>57701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78793</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77025</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78240</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gottingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Muenster</city>
        <zip>48145</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tuebingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Arecibo</city>
        <zip>00612</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sevilla</city>
        <state>Andalucia</state>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sant Cugat</city>
        <state>Catalunya</state>
        <zip>08190</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Cataluña</state>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Puerto Rico</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>April 23, 2019</study_first_submitted>
  <study_first_submitted_qc>April 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 25, 2019</study_first_posted>
  <last_update_submitted>March 13, 2020</last_update_submitted>
  <last_update_submitted_qc>March 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranibizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

